Mining the mutanome

Developing highly personalized Immunotherapies based on mutational analysis of tumors

Willem W. Overwijk, Ena Wang, Francesco M. Marincola, Hans Georg Rammensee, Nicholas P. Restifo, Organizing Committee of the 2013 SITC Workshop on Personalized Immunotherapy

Research output: Contribution to journalReview article

42 Citations (Scopus)

Abstract

T cells can mediate remarkable tumor regressions including complete cure in patients with metastatic cancer. Genetic alterations in an individual's cancer cells (the mutanome) encode unique peptides (m-peptides) that can be targets for T cells. The recent advances in next-generation sequencing and computation prediction allows, for the first time, the rapid and affordable identification of m-peptides in individual patients. Despite excitement about the extended spectrum of potential targets in personalized immunotherapy, there is no experience or consensus on the path to their successful clinical application. Major questions remain, such as whether clinical responses to cytokine therapy, T cell transfer, and checkpoint blockade are primarily mediated by m-peptide-specific reactivity, whether m-peptides can be effectively used as vaccines, and which m-peptides are most potently recognized. These and other technological, immunological and translational questions will be explored during a 1-day Workshop on Personalized Cancer Immunotherapy by the Society for Immunotherapy of Cancer, directly before the Annual Meeting, on November 7, 2013 at the National Harbor, MD near Washington, DC.

Original languageEnglish
Article number11
JournalJournal for ImmunoTherapy of Cancer
Volume1
DOIs
Publication statusPublished - 2013
Externally publishedYes

Fingerprint

Immunotherapy
Peptides
Neoplasms
T-Lymphocytes
Vaccines
Cytokines
Education
Therapeutics

Keywords

  • Checkpoint blockade
  • Exome
  • Mutanome
  • Mutation
  • Neoantigen
  • Next-generation sequencing
  • Omics
  • Peptide epitope
  • T lymphocyte
  • Vaccine

ASJC Scopus subject areas

  • Oncology
  • Immunology and Allergy
  • Cancer Research
  • Molecular Medicine
  • Pharmacology
  • Immunology

Cite this

Overwijk, W. W., Wang, E., Marincola, F. M., Rammensee, H. G., Restifo, N. P., & Organizing Committee of the 2013 SITC Workshop on Personalized Immunotherapy (2013). Mining the mutanome: Developing highly personalized Immunotherapies based on mutational analysis of tumors. Journal for ImmunoTherapy of Cancer, 1, [11]. https://doi.org/10.1186/2051-1426-1-11

Mining the mutanome : Developing highly personalized Immunotherapies based on mutational analysis of tumors. / Overwijk, Willem W.; Wang, Ena; Marincola, Francesco M.; Rammensee, Hans Georg; Restifo, Nicholas P.; Organizing Committee of the 2013 SITC Workshop on Personalized Immunotherapy.

In: Journal for ImmunoTherapy of Cancer, Vol. 1, 11, 2013.

Research output: Contribution to journalReview article

Overwijk, WW, Wang, E, Marincola, FM, Rammensee, HG, Restifo, NP & Organizing Committee of the 2013 SITC Workshop on Personalized Immunotherapy 2013, 'Mining the mutanome: Developing highly personalized Immunotherapies based on mutational analysis of tumors', Journal for ImmunoTherapy of Cancer, vol. 1, 11. https://doi.org/10.1186/2051-1426-1-11
Overwijk WW, Wang E, Marincola FM, Rammensee HG, Restifo NP, Organizing Committee of the 2013 SITC Workshop on Personalized Immunotherapy. Mining the mutanome: Developing highly personalized Immunotherapies based on mutational analysis of tumors. Journal for ImmunoTherapy of Cancer. 2013;1. 11. https://doi.org/10.1186/2051-1426-1-11
Overwijk, Willem W. ; Wang, Ena ; Marincola, Francesco M. ; Rammensee, Hans Georg ; Restifo, Nicholas P. ; Organizing Committee of the 2013 SITC Workshop on Personalized Immunotherapy. / Mining the mutanome : Developing highly personalized Immunotherapies based on mutational analysis of tumors. In: Journal for ImmunoTherapy of Cancer. 2013 ; Vol. 1.
@article{85e68aa26b1a4b2e8e5690e2f2fc3272,
title = "Mining the mutanome: Developing highly personalized Immunotherapies based on mutational analysis of tumors",
abstract = "T cells can mediate remarkable tumor regressions including complete cure in patients with metastatic cancer. Genetic alterations in an individual's cancer cells (the mutanome) encode unique peptides (m-peptides) that can be targets for T cells. The recent advances in next-generation sequencing and computation prediction allows, for the first time, the rapid and affordable identification of m-peptides in individual patients. Despite excitement about the extended spectrum of potential targets in personalized immunotherapy, there is no experience or consensus on the path to their successful clinical application. Major questions remain, such as whether clinical responses to cytokine therapy, T cell transfer, and checkpoint blockade are primarily mediated by m-peptide-specific reactivity, whether m-peptides can be effectively used as vaccines, and which m-peptides are most potently recognized. These and other technological, immunological and translational questions will be explored during a 1-day Workshop on Personalized Cancer Immunotherapy by the Society for Immunotherapy of Cancer, directly before the Annual Meeting, on November 7, 2013 at the National Harbor, MD near Washington, DC.",
keywords = "Checkpoint blockade, Exome, Mutanome, Mutation, Neoantigen, Next-generation sequencing, Omics, Peptide epitope, T lymphocyte, Vaccine",
author = "Overwijk, {Willem W.} and Ena Wang and Marincola, {Francesco M.} and Rammensee, {Hans Georg} and Restifo, {Nicholas P.} and {Organizing Committee of the 2013 SITC Workshop on Personalized Immunotherapy}",
year = "2013",
doi = "10.1186/2051-1426-1-11",
language = "English",
volume = "1",
journal = "Journal for ImmunoTherapy of Cancer",
issn = "2051-1426",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Mining the mutanome

T2 - Developing highly personalized Immunotherapies based on mutational analysis of tumors

AU - Overwijk, Willem W.

AU - Wang, Ena

AU - Marincola, Francesco M.

AU - Rammensee, Hans Georg

AU - Restifo, Nicholas P.

AU - Organizing Committee of the 2013 SITC Workshop on Personalized Immunotherapy

PY - 2013

Y1 - 2013

N2 - T cells can mediate remarkable tumor regressions including complete cure in patients with metastatic cancer. Genetic alterations in an individual's cancer cells (the mutanome) encode unique peptides (m-peptides) that can be targets for T cells. The recent advances in next-generation sequencing and computation prediction allows, for the first time, the rapid and affordable identification of m-peptides in individual patients. Despite excitement about the extended spectrum of potential targets in personalized immunotherapy, there is no experience or consensus on the path to their successful clinical application. Major questions remain, such as whether clinical responses to cytokine therapy, T cell transfer, and checkpoint blockade are primarily mediated by m-peptide-specific reactivity, whether m-peptides can be effectively used as vaccines, and which m-peptides are most potently recognized. These and other technological, immunological and translational questions will be explored during a 1-day Workshop on Personalized Cancer Immunotherapy by the Society for Immunotherapy of Cancer, directly before the Annual Meeting, on November 7, 2013 at the National Harbor, MD near Washington, DC.

AB - T cells can mediate remarkable tumor regressions including complete cure in patients with metastatic cancer. Genetic alterations in an individual's cancer cells (the mutanome) encode unique peptides (m-peptides) that can be targets for T cells. The recent advances in next-generation sequencing and computation prediction allows, for the first time, the rapid and affordable identification of m-peptides in individual patients. Despite excitement about the extended spectrum of potential targets in personalized immunotherapy, there is no experience or consensus on the path to their successful clinical application. Major questions remain, such as whether clinical responses to cytokine therapy, T cell transfer, and checkpoint blockade are primarily mediated by m-peptide-specific reactivity, whether m-peptides can be effectively used as vaccines, and which m-peptides are most potently recognized. These and other technological, immunological and translational questions will be explored during a 1-day Workshop on Personalized Cancer Immunotherapy by the Society for Immunotherapy of Cancer, directly before the Annual Meeting, on November 7, 2013 at the National Harbor, MD near Washington, DC.

KW - Checkpoint blockade

KW - Exome

KW - Mutanome

KW - Mutation

KW - Neoantigen

KW - Next-generation sequencing

KW - Omics

KW - Peptide epitope

KW - T lymphocyte

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84991030590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991030590&partnerID=8YFLogxK

U2 - 10.1186/2051-1426-1-11

DO - 10.1186/2051-1426-1-11

M3 - Review article

VL - 1

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

SN - 2051-1426

M1 - 11

ER -